4.6 Article

Nit1 and Fhit Tumor Suppressor Activities Are Additive

Journal

JOURNAL OF CELLULAR BIOCHEMISTRY
Volume 107, Issue 6, Pages 1097-1106

Publisher

WILEY
DOI: 10.1002/jcb.22207

Keywords

NIT1; FHIT; NMBA TUMOR INDUCTION; TUMOR SUPPRESSOR

Funding

  1. National Institutes Of Health [CA77738, CA132453]

Ask authors/readers for more resources

The fragile histidine triad gene (human FHIT, mouse Fhit) has been shown to act as a tumor suppressor gene. Nit1 and Fhit form a fusion protein, encoded by the NitFhit gene in flies and worms, suggesting that mammalian Nit1 and Fhit proteins, which are encoded by genes on different chromosomes in mammals, may function in the same signal pathway(s). A previous study showed that Nit1 deficiency in knockout mice confers a cancer prone phenotype, as does Fhit deficiency. We have now assessed the tumor susceptibility of Fhit(-/-)Nit1(-/-) mice and observed that double knockout mice develop more spontaneous and carcinogen-induced tumors than Fhit(-/-) mice, suggesting that the extent of tumor susceptibility due to Nit1 and Fhit deficiency is additive, and that Nit1 and Fhit affect distinct signal pathways in mammals. Nit1, like Fhit, is present in cytoplasm and mitochondria but not nuclei. Because Fhit deficiency affects responses to replicative and oxidative stress, we sought evidence for Nit I function in response to such stresses in tissues and cultured cells: when treated with hydroxyurea, the normal kidney-derived double-deficient cells appear not to activate the pChk2 pathway and when treated with H2O2, show little evidence of DNA damage, compared with wild type and Fhit(-/-) cells. The relevance of Nit1 deficiency to human cancers was examined in human esophageal cancer tissues, and loss of Nit1 expression was observed in 48% of esophageal adenocarcinomas. J. Cell. Biochem. 107: 1097-1106, 2009. (C) 2009 Wiley-Liss, Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Pathology

Perineural invasion predicts for locoregional failure in patients with oesophageal adenocarcinoma treated with neoadjuvant chemoradiotherapy

Ankur K. Patel, Xueliang Pan, Diana M. Vila, Wendy L. Frankel, Wei Chen, Kyle A. Perry, Robert E. Merritt, Desmond M. D'Souza, Evan J. Wuthrick, Terence M. Williams

Summary: The study found that the presence of PNI in EAC patients during surgery is significantly associated with worse LRFS and DFS, indicating that considering adjuvant therapy in PNI patients may be beneficial.

JOURNAL OF CLINICAL PATHOLOGY (2021)

Article Pathology

Activation of the RAS pathway through uncommonBRAFmutations in mucinous pancreatic cysts withoutKRASmutation

Rongqin Ren, Somashekar G. Krishna, Wei Chen, Wendy L. Frankel, Rulong Shen, Weiqiang Zhao, Matthew R. Avenarius, Jason Garee, Sean Caruthers, Dan Jones

Summary: Molecular testing for KRAS/GNAS mutations can improve the accuracy of detecting mucinous pancreatic cystic lesions. Using next-generation sequencing, the status of PCL-associated mutations can be assessed to enhance diagnostic understanding.

MODERN PATHOLOGY (2021)

Article Oncology

Double somatic mismatch repair gene pathogenic variants as common as Lynch syndrome among endometrial cancer patients

Heather Hampel, Rachel Pearlman, Albert de la Chapelle, Colin C. Pritchard, Weiqiang Zhao, Dan Jones, Ahmet Yilmaz, Wei Chen, Wendy L. Frankel, Adrian A. Suarez, Casey Cosgrove, Floor Backes, Larry Copeland, Jeffrey Fowler, David O'Malley, Ritu Salani, Joseph P. McElroy, Peter P. Stanich, Paul Goodfellow, David E. Cohn

Summary: The study revealed that double somatic MMR gene PV are as common as Lynch syndrome among endometrial cancer patients. Paired tumor and germline testing for patients with non-methylated dMMR tumor may be the most efficient approach for Lynch syndrome screening.

GYNECOLOGIC ONCOLOGY (2021)

Article Cell Biology

Histopathological diagnosis of tumour deposits in colorectal cancer: a Delphi consensus study

Amy Lord, Gina Brown, Muti Abulafi, Adrian Bateman, Wendy Frankel, Robert Goldin, Purva Gopal, Richard Kirsch, Maurice B. Loughrey, Bruno Maerkl, Brendan Moran, Giacomo Puppa, Shahnawaz Rasheed, Yoshifumi Shimada, Petur Snaebjornsson, Magali Svrcek, Kay Washington, Nicholas West, Newton Wong, Iris Nagtegaal

Summary: Tumour deposits (TDs) are an important prognostic marker in colorectal cancer, but their classification and inclusion in staging are controversial. Expert consensus suggests a need for a clearer, more reproducible definition of TDs, and the recommendation to record the number of TDs and not exclude nodules with evidence of origin.

HISTOPATHOLOGY (2021)

Article Pathology

Morphologic changes associated with neoadjuvant-treated pancreatic ductal adenocarcinoma and comparison of two tumor regression grading systems

Jennifer Vazzano, Wendy L. Frankel, Adam R. Wolfe, Terence M. Williams, Wei Chen

Summary: This study analyzed PDAC cases and found significant histologic differences between NAT and non-NAT cases, with blue/grey fibrosis being a useful clue to suggest the possibility of adjacent tumor in the majority of PDAC cases. Interestingly, while neither grading scheme correlated with overall survival, the MDA score was significantly correlated with time to primary tumor recurrence and time to distant recurrence.

HUMAN PATHOLOGY (2021)

Article Medical Laboratory Technology

Pancreatic Frozen Section Guides Operative Management With Few Deferrals and Errors Five-Year Experience at a Large Academic Institution

Jesus A. Chavez, Wei Chen, C. Eric Freitag, Wendy L. Frankel

Summary: This study evaluated the use and accuracy of frozen section in pancreatic resections and how diagnosis impacts surgical procedure. The results showed that frozen section remains an important diagnostic tool in pancreatectomy, with high accuracy and occasional deferrals.

ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2022)

Article Medical Laboratory Technology

Digital Pathology Initiatives and Experience of a Large Academic Institution During the Coronavirus Disease 2019 (COVID-19) Pandemic

Giovanni M. Lujan, Johanna Savage, Arwa Shana'ah, Martha Yearsley, Diana Thomas, Patricia Allenby, Jose Otero, Abberly Lott Limbach, Xiaoyan Cui, Rachel T. Scarl, Tanner Hardy, Jesse Sheldon, Jose A. Plaza, Bonnie Whitaker, Wendy Frankel, Anil V. Parwani, Zaibo Li

Summary: The pandemic acted as a catalyst for pathologists to adopt a digital workflow into their daily practice, realizing the logistic and technical advantages of such tools.

ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2021)

Article Oncology

Using Endoscopic Optical Coherence Tomography to Detect and Treat Early-Stage Pancreatic Cancers

Lanchun Lu, Zhilin Hu, Wendy Frankel, Rulong Shen, Wei Chen, Xueliang Pan, John C. Grecula, Mark P. Bloomston, Mary E. Dillhoff

Summary: The novel technology integrates high-resolution three-dimensional endoscopic optical coherence tomography (Endo-OCT) for early-stage pancreatic cancer detection and high dose rate brachytherapy (HDR) for treatment under Endo-OCT image guidance. It offers a compact, portable, easy-to-operate, and low-cost system with dual functions of diagnosis and treatment to reduce potential complications from surgery and high operation costs.

FRONTIERS IN ONCOLOGY (2021)

Article Oncology

Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial

Karyn A. Goodman, Fang-Shu Ou, Nathan C. Hall, Tanios Bekaii-Saab, Briant Fruth, Erin Twohy, Michael O. Meyers, Daniel J. Boffa, Kisha Mitchell, Wendy L. Frankel, Donna Niedzwiecki, Anne Noonan, Yelena Y. Janjigian, Paul J. Thurmes, Alan P. Venook, Jeffrey A. Meyerhardt, Eileen M. O'Reilly, David H. Ilson

Summary: The study evaluated the use of early assessment of chemotherapy responsiveness by PET imaging to tailor therapy for patients with esophageal and esophagogastric junction adenocarcinoma. Results showed improved pathologic complete response rates in PET nonresponders, with PET responders to FOLFOX achieving a promising 5-year overall survival of 53%.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Article Oncology

Neuropeptide Y, a paracrine factor secreted by cancer cells, is an independent regulator of angiogenesis in colon cancer

Debanjan Chakroborty, Sandeep Goswami, Hao Fan, Wendy L. Frankel, Sujit Basu, Chandrani Sarkar

Summary: This study found that NPY and Y2R are overexpressed in colon adenocarcinoma. Treatment with Y2R antagonists can inhibit angiogenesis and tumor growth. NPY regulates the angiogenic potential of colonic endothelial cells through Y2R and activates the ERK/MAPK signaling pathway.

BRITISH JOURNAL OF CANCER (2022)

Article Oncology

Universal tumor screening for lynch syndrome on colorectal cancer biopsies impacts surgical treatment decisions

Jennifer Vazzano, Jewel Tomlinson, Peter P. Stanich, Rachel Pearlman, Matthew F. Kalady, Wei Chen, Heather Hampel, Wendy L. Frankel

Summary: This study examined the utilization of universal tumor screening (UTS) on colorectal cancer (CRC) patients and evaluated the impact of genetic counseling and testing on surgical decisions. The results showed that UTS performed on biopsies provided valuable information for genetic counseling and testing, leading to informed surgical decisions.

FAMILIAL CANCER (2023)

Article Oncology

Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas The A021501 Phase 2 Randomized Clinical Trial

Matthew H. G. Katz, Qian Shi, Jeff Meyers, Joseph M. Herman, Michael Chuong, Brian M. Wolpin, Syed Ahmad, Robert Marsh, Larry Schwartz, Spencer Behr, Wendy L. Frankel, Eric Collisson, James Leenstra, Terence M. Williams, Gina Vaccaro, Alan Venook, Jeffrey A. Meyerhardt, Eileen M. O'Reilly

Summary: This randomized clinical trial found that treatment with neoadjuvant modified FOLFIRINOX alone was associated with favorable overall survival (OS) in patients with borderline resectable pancreatic ductal adenocarcinoma (PDAC) compared with treatment with modified FOLFIRINOX plus hypofractionated radiotherapy. Therefore, modified FOLFIRINOX represents a reference regimen in this setting.

JAMA ONCOLOGY (2022)

Article Pathology

Mismatch repair protein status of non-neoplastic uterine and intestinal mucosa in patients with Lynch syndrome and double somatic mismatch repair protein mutations

C. Eric Freitag, Wei Chen, Rachel Pearlman, Heather Hampel, Peter P. Stanich, Casey M. Cosgrove, Eric Q. Konnick, Colin C. Pritchard, Wendy L. Frankel

Summary: Mismatch repair (MMR) protein-deficient colonic crypts and endometrial glands (dMMR crypts and glands) are unique markers of underlying Lynch syndrome (LS) and are rarer in double somatic (DS) MMR-mutated cases. A retrospective analysis of colonic resection specimens and endometrial specimens revealed that dMMR crypts were more frequent in LS cases compared to DS cases, while dMMR glands were also more common in LS cases than in DS cases. The presence of dMMR crypts and glands is highly associated with LS.

HUMAN PATHOLOGY (2023)

Article Pathology

Ampulla of Vater biopsies: A retrospective 10-year, single-institution study

Denise Gamble, Wendy L. Frankel, Martha M. Yearsley, Wei Chen

Summary: Endoscopic biopsies of the ampulla of Vater are challenging due to sampling limitations and the complexity of local anatomy. A retrospective review of 318 biopsy specimens from 252 patients found that a significant proportion of cases were diagnosed as adenoma or adenocarcinoma. Follow-up specimens showed discordant results in 38.9% of cases, with major discrepancies observed in 22.9% of cases.

ANNALS OF DIAGNOSTIC PATHOLOGY (2023)

Article Oncology

Prospective Statewide Study of Universal Screening for Hereditary Colorectal Cancer: The Ohio Colorectal Cancer Prevention Initiative

Rachel Pearlman, Wendy L. Frankel, Benjamin J. Swanson, Dan Jones, Weiqiang Zhao, Ahmet Yilmaz, Kristin Miller, Jason Bacher, Christopher Bigley, Lori Nelsen, Paul J. Goodfellow, Richard M. Goldberg, Electra Paskett, Peter G. Shields, Jo L. Freudenheim, Peter P. Stanich, Ilene Lattimer, Mark Arnold, Thomas W. Prior, Mitchell Haut, Matthew F. Kalady, Brandie Heald, Ian Paquette, David J. Draper, Joanna M. Brell, Sameer Mahesh, Kisa Weeman, Shyamal Bastola, Jeffrey Zangmeister, Aruna Gowda, Filix Kencana, Albert Malcolm, Yinong Liu, Sharon Cole, Charles Bane, Chaoyang Li, Esther Rehmus, Colin C. Pritchard, Brian H. Shirts, Angela Jacobson, Shelly A. Cummings, Albert de la Chapelle, Heather Hampel

Summary: The study found that 7.1% of individuals with CRC have PGVs, and UTS alone is insufficient for identifying a large proportion of CRC patients with hereditary syndromes, including some with LS. Pan-cancer MGPT for all patients with CRC may be a better screening method.

JCO PRECISION ONCOLOGY (2021)

No Data Available